headerhome

Opening New Frontiers By Advancing The Promise of PI Signaling Pathways

Nathanael S. Gray, Ph.D.

Select a team to find out more

Nathanael S. Gray, Ph.D.

Nathanael S. Gray, Ph.D.

Scientific Co-Founder and Chairman SAB, Petra Pharma, and Professor, Harvard Medical School and Dana-Farber Cancer Institute

Dr. Nathanael Gray spent his childhood in Zambia, Yemen, India and Sudan before returning to the U.S. to attend high school at Berkeley High in California.  Nathanael earned a Ph.D. in organic chemistry in 1999 from the University of California at Berkeley where he discovered Purvalanol, one of the first selective inhibitors of cyclin-dependent kinases.  Later, Nathanael moved to the Genomics Institute of the Novartis Research Foundation, where he was named director of biological chemistry in 2001 after serving as a staff scientist and group leader of kinase inhibitor chemistry.  His research team was responsible for the development of several clinical candidates, including BAF312 which is currently undergoing phase 3 clinical trials for the treatment of multiple sclerosis.

Nathanael joined the faculty of Harvard Medical School and the Dana Farber Cancer Institute in 2006 to continue his research using synthetic chemistry and functional small molecule discovery to modulate biological pathways important in cancer.  His research group has been responsible for the discovery of novel inhibitors of wild-type and mutant forms of EGFR (WZ4002), mTor (Torin1 and Torin 2), Bcr-Abl (GNF-2, GNF-5, HG-7-85-01), Mps1 (Mps1-IN-1 Mps1-IN-2), Erk5 (XMD8-92), b-Raf, LRRK2 (LRRK2-IN-1), Jnk1,2,3 (JNK-IN-7) and Ephrin kinases which have become widely used research tools and have inspired several drug discovery programs.

timelinearrowleft

timelinearrowright